Please login to the form below

Not currently logged in
Email:
Password:

polycythemia vera

This page shows the latest polycythemia vera news and features for those working in and with pharma, biotech and healthcare.

FDA turns down Celgene’s filing for multiple sclerosis drug

FDA turns down Celgene’s filing for multiple sclerosis drug

$7bn for Impact Biomedicines to add late-stage candidate fedratinib for myelofibrosis and polycythemia vera.

Latest news

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    and polycythemia vera, both rare bone marrow cancers. ... Acquisition company - remaining 90%. 9, 000. Impact Biomedicines/ Celgene. Fedratinib, highly selective JAK2 kinase inhibitor for myelofibrosis (p3) and polycythemia vera.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics